The treatment of pediatric inflammatory bowel disease has been revolutionized by the advent of biologic therapies, which have been shown to effectively treat symptoms, induce mucosal healing, and reverse growth impairment in many patients. However, experts continue to debate the positioning of biologics in IBD, and are seeking ways to better understand how to deliver optimal treatment to children affected by the disease.
Pediatric IBD rates are on the rise globally, and the 20% to 30% of patients with IBD onset before age 20 years often have more extensive, severe and complicated disease compared with those whose disease presents in adulthood. According to experts interviewed by
Healio Gastroenterology, early treatment with biologics provides newfound hope for preventing these complications, though many factors must be considered when choosing an initial therapy for children. Unfortunately, despite their availability and impact, several barriers prevent the use of biologics as first-line therapies.
Payers, Guidelines Discrepancies
One major obstacle, experts agreed, is that most insurance policies require step-wise failure of conventional treatments before approving a biologic therapy.
A recent study published in
Inflammatory Bowel Diseasesevaluated the criteria for approval of biologics and showed that the majority “do not comply with the current standard of care for treating IBD based on the severity of disease and best available pharmacologic therapy.” Why these policies require certain drugs to fail before considering biologics is unclear, according to study investigator
Joseph D. Feuerstein, MD, of the division of gastroenterology at Beth Israel Deaconess Medical Center, Harvard Medical School, and colleagues.
“There are no clinical studies to indicate that mesalamine must be tried and proved unsuccessful before infliximab [Remicade, Janssen] or vedolizumab [Entyvio, Takeda] can be considered,” they wrote. “In contrast, delaying appropriate therapy results in ongoing disease activity and resultant complications.”
Jeffrey S. Hyams
This study showed that AGA guideline recommendations on the early use of biologics for patients with moderate-to-severe disease “are totally unaligned with insurance company policies requiring the failure of multiple agents before biologics are approved,”
Jeffrey S. Hyams, MD, of the division of digestive diseases, hepatology, and nutrition at Connecticut Children’s Medical Center, said in an interview.
This is especially problematic for pediatric gastroenterologists, as insurance companies do not have separate treatment policies for children and adults even though children “require a much different approach,” he added. “One does not have an opportunity to wait for weeks to months in a sick child with growth failure to be treated with long-term corticosteroids and to wait for immunomodulators to fail. ... One doesn’t have that window in pediatrics, so there is a big disconnect between the insurers and what has become standard of practice.”